Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krka DDFRA:KN8 72 Debt-to-EBITDA is 0.02 as of Jun. 2026, which is 33% below its 10-year median of 0.03. GuruFocus rates FRA:KN8 with a GF Score™ of 72/100 and a GF Value™ of €208.35 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 681 Drug Manufacturers companies, Krka DD ranks better than 95.15% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Krka DD's Debt-to-EBITDA or its related term are showing as below:
FRA:KN8'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 0.24
Current: 0.03
During the past 13 years, the highest Debt-to-EBITDA Ratio of Krka DD was 0.24. The lowest was 0.00. And the median was 0.03.
FRA:KN8's Debt-to-EBITDA is ranked better than 95.15% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs FRA:KN8: 0.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Krka DD Debt-to-EBITDA Related Terms
Krka DD Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Krka DD's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:KN8 vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Krka DD's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Krka DD (FRA:KN8) has a Debt-to-EBITDA of 0.02 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Krka DD. This is 33% below median its historical median of 0.03. According to the industry distribution chart, Krka DD ranks #33 out of 681 companies in the Drug Manufacturers industry, placing it in the top 4.8%.
Is Krka DD's Debt-to-EBITDA too high?
Krka DD's current Debt-to-EBITDA of 0.02 is 33% below median its 10-year median of 0.03. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Krka DD's value of 0.02 is 98.8% below this industry median. Based on the distribution chart, Krka DD ranks #33 out of 681 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Krka DD has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #33 out of 681 companies for Debt-to-EBITDA. This places Krka DD in the top 5% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.63. Krka DD's value of 0.02 is 98.8% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 1.63, Krka DD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current Debt-to-EBITDA of 0.02 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Krka DD. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current Debt-to-EBITDA is 0.02, which is 33% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Modestly Overvalued. The stock's GF Value™ is €208.35, compared to a current price of €258.00 — trading 23.8% above its estimated fair value. The current Debt-to-EBITDA is 0.02, which is 33% below median its 10-year median of 0.03 and 98.8% below the Drug Manufacturers industry median of 1.63. Krka DD's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current Debt-to-EBITDA is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (FRA:KN8) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €258.00 is trading 23.8% above its estimated GF Value™ of €208.35.
GuruFocus considers Krka DD to be Modestly Overvalued.
Key valuation signals for FRA:KN8:
Debt-to-EBITDA: 0.02 (33% below median its 10-year median of 0.03)
GF Value™: €208.35 vs. price of €258.00 (23.8% above fair value)
Industry Position: 98.8% below the Drug Manufacturers median (#33 of 681)
No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
72GF Score
Get the complete analysis for FRA:KN8
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN8 has been successfully added to your 
